Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 April 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Neoadjuvant chemo for rectal cancer to be applied cautiously

Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution for advanced rectal cancer, and the latest British Journal of Cancer suggests concurrent chemoradiation with radiotherapy as the best option.

News image

fiogf49gjkf04

Neoadjuvant chemotherapy is a term originally used to describe the administration of chemotherapy preoperatively before surgery.

Neoadjuvant chemotherapy is induced chemotherapy to shrink or downstage a locally advanced tumor.

It thereby facilitates more effective local treatment with surgery or radiotherapy.

The method has been extended with more effective combinations of chemotherapy to reduce the risks of metastatic disease.

It seems logical that survival could be lengthened, or organ preservation rates increased in resectable tumors by neoadjuvant chemotherapy.

In rectal cancer neoadjuvant chemotherapy is being increasingly used in locally advanced and nonmetastatic unresectable tumors.

Randomized studies in advanced colorectal cancer show high response rates to combination cytotoxic therapy.

This evidence of efficacy coupled with the introduction of novel molecular targeted therapies have rekindled an interest in neoadjuvant chemotherapy.

Long waiting times for radiotherapy have also increased interest in delivering neoadjuvant chemotherapy in locally advanced rectal cancer.

In contrast, this enthusiasm is waning for sites such as head and neck, and nasopharynx cancer where traditionally neoadjuvant chemotherapy has been used.

The question arises whether neoadjuvant chemotherapy in rectal cancer a real advance or just history repeating itself.

Dr Glynne-Jones and colleagues from England explored the advantages and disadvantages of the separate approaches of chemotherapy.

The research team undertook a review of neoadjuvant, concurrent and consolidation chemotherapy in locally advanced rectal cancer.

The researchers drew on theoretical principles, preclinical studies and clinical experience both in rectal cancer and other disease sites.

The team found that neoadjuvant chemotherapy may improve outcome in terms of disease-free or overall survival in selected groups in some disease sites.

However, the researchers noted that this strategy has not been shown to be associated with better outcomes than postoperative adjuvant chemotherapy.

Neoadjuvant chemotherapy does not appear to enhance local control
British Journal of Cancer

In particular, the team highlighted that there is insufficient data in rectal cancer.

The evidence for benefit is strongest when neoadjuvant chemotherapy is administered before surgical resection.

In contrast, the data in favour of neoadjuvant chemotherapy before radiation or chemoradiation is inconclusive.

The team noted these findings despite the suggestion that response to induction chemotherapy can predict response to subsequent radiotherapy.

The observation that spectacular responses to chemotherapy before radical radiotherapy did not result in improved survival, was noted 25 years ago.

Multiple trials in head and neck cancer, nasopharyngeal cancer, and non-small-cell lung cancer, do no support the routine use of neoadjuvant chemotherapy.

The researchers also found that trials in small-cell lung cancer and cervical cancer do not support the routine use of neoadjuvant chemotherapy.

The trials identified did not advocate the use of neoadjuvant chemotherapy either as an alternative, or as additional benefit to chemoradiation.

The addition of neoadjuvant chemotherapy does not appear to enhance local control over concurrent chemoradiation or radiotherapy alone.

Dr Glynne-Jones' team concluded, “Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution, and only in the context of clinical trials.”

“The evidence base suggests that concurrent chemoradiation with early positioning of radiotherapy appears the best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy.”

Br J Canc 2006: 94: 363-71
16 February 2006

Go to top of page Email this page Email this page to a colleague

 19 April 2018 
Fibrosis in patients with chronic hepatitis B
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA
 18 April 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 18 April 2018 
Hep C treatment for sustained virologic response
 18 April 2018 
Endoscopic necrosectomy reduces risk of death 
 17 April 2018 
Colorectal cancer screening and ethnic inequities
 17 April 2018 
Training programs should consider radiation education for advanced endoscopy fellows
 17 April 2018 
Aspirin and pancreatic cancer
 16 April 2018 
Surgery for colorectal polyps has increased 
 16 April 2018 
Advanced fibrosis can be ruled out in primary health care patients
 16 April 2018 
Antibiotic use and colorectal adenoma
 13 April 2018 
Colorectal cancer cell lines
 13 April 2018 
Infliximab and corticosteroid-free clinical remission in Crohn's
 13 April 2018 
Teduglutide for children with short bowel syndrome
 12 April 2018 
Prescriptions for opiate drugs amongst primary care patients with IBD
 12 April 2018 
Lower GI bleeding related to comorbidity
 12 April 2018 
non–Clostridium difficile bacterial infections in IBD
 11 April 2018 
Physician perception of IBD trial results
 11 April 2018 
Bile acid deficiency in IBS 
 11 April 2018 
Stem cell therapy for fistulas in Crohn's
 10 April 2018 
Overweight in childhood and type 2 diabetes
 10 April 2018 
immunoglobulin G associates with clinical features of IBD
 10 April 2018 
T-cells repertoires in celiac disease
 09 April 2018 
Biomarker tests for colorectal cancer screening
 09 April 2018 
Fecal transplantation in C. difficile infection and treatment outcome 
 09 April 2018 
No weigh-loss drug improved all cardiometabolic risk factors
 06 April 2018 
Colonoscopy and colorectal cancer mortality
 06 April 2018 
Eosinophilic esophagitis and health-related quality of life
 06 April 2018 
Microbiome in athletes vs sedentary subjects
 05 April 2018 
Laparoscopic Nissen fundoplication for GERD treatment
 05 April 2018 
Random biopsies for neoplasia in IBD
 05 April 2018 
Scoring system identifies cancer risk in Barrett's
 04 April 2018 
Alpha‐1 antitrypsin deficiency and liver disease
 04 April 2018 
PPI and risk of stroke
 04 April 2018 
Adjuvant chemotherapy for advanced colon cancer
 29 March 2018 
Worldwide H.pylori prevalence
 29 March 2018 
Prevention of metachronous gastric cancer
 29 March 2018 
Acute lower GI bleeding
 28 March 2018 
Decision aid used by IBD patients
 28 March 2018 
Transition for young adults with IBD
 28 March 2018 
Amitriptyline in functional dyspepsia
 27 March 2018 
Emergency department utilization for IBD 
 27 March 2018 
Management of hemorrhoids in the USA
 27 March 2018 
Adult ulcerative colitis
 26 March 2018 
Biological therapy response in IBD 
 26 March 2018 
Obesity and diverticulosis
 26 March 2018 
Practice guidelines for chronic constipation
 23 March 2018 
Health-related quality of life in eosinophilic esophagitis
 23 March 2018 
Genetics and chronic liver disease
 23 March 2018 
Global prevalence of H.pylori
 22 March 2018 
H. pyloris and gastric cancer
 22 March 2018 
Pancreatitis after IBS treatment 
 22 March 2018 
Mechanisms of action in patients with IBS
 21 March 2018 
Panel markers for early detection of colon cancer

 21 March 2018 
Blood test differentiates celiac disease
 21 March 2018 
Patient characteristics and colonoscopy preparation
 20 March 2018 
Bloody vs coffee-grounds hematemesis
 20 March 2018 
Acute lower GI bleeding in the UK
 20 March 2018 
Therapeutic strategies for IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us